Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Generali Investments Management Co LLC

Generali Investments Management Co LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,276 shares of the biopharmaceutical company’s stock after selling 766 shares during the period. Generali Investments Management Co LLC’s holdings in Regeneron Pharmaceuticals were worth $796,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. E. Ohman J or Asset Management AB grew its position in Regeneron Pharmaceuticals by 35.2% during the second quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock valued at $2,394,000 after buying an additional 1,000 shares during the period. Harrell Investment Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the second quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock worth $1,303,000 after acquiring an additional 27 shares during the period. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $6,327,000. Allied Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Jacobs & Co. CA boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Jacobs & Co. CA now owns 10,372 shares of the biopharmaceutical company’s stock worth $6,467,000 after acquiring an additional 95 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 3.0%

Shares of REGN opened at $808.05 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $661.43 and its two-hundred day moving average is $712.70. The stock has a market cap of $83.20 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 1.33 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $12.81 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Truist Financial increased their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Finally, HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $797.75.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.